Pulmatrix: Plumatrix to merge with Cullgen Inc.
Pulmatrix, a clinical-stage biopharmaceutical company, announced a merger agreement with Cullgen Inc., a privately-held, clinical-stage biopharmaceutical company applying its proprietary targeted protein degradation uSMITE platform to discover and advance therapeutics for the treatment of cancer and other diseases
Read full article »
Pulmatrix is a Massachusetts-based biopharmaceutical firm that develops and commercializes therapies for the treatment of pulmonary and non-pulmonary diseases.
Read more